Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment Guidelines for Community-acquired Pneumonia in Korea: An Evidence-based Approach to Appropriate Antimicrobial Therapy

지역사회획득 폐렴의 치료지침 권고안

  • Song, Jae-Hoon (Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jung, Ki-Suck (Hallym University Sacred Heart Hospital) ;
  • Kang, Moon Won (Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Do Jin (Soonchunhyang University Bucheon Hospital) ;
  • Pai, Hyunjoo (Hanyang University Hospital) ;
  • Suh, Gee Young (Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Shim, Tae Sun (University of Ulsan College of Medicine, Asan Medical Center) ;
  • Ahn, Joong Hyun (Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Ahn, Chul Min (Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Woo, Jun Hee (University of Ulsan College of Medicine, Asan Medical Center) ;
  • Lee, Nam Yong (Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Dong-Gun (Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Lee, Mi Suk (Kyung Hee University Medical Center, Kyung Hee University School of Medicine) ;
  • Lee, Sang Moo (Health Insurance Review & Assessment Service) ;
  • Lee, Yeong Seon (Korea Centers for Disease Control and Prevention) ;
  • Lee, Hyukmin (Kwandong University Myongji Hospital) ;
  • Chung, Doo Ryeon (Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 송재훈 (성균관대학교 의과대학 삼성서울병원) ;
  • 정기석 (한림대학교성심병원) ;
  • 강문원 (가톨릭대학교 의과대학 서울성모병원) ;
  • 김도진 (순천향대학교 부천병원) ;
  • 배현주 (한양대학교병원) ;
  • 서지영 (성균관대학교 의과대학 삼성서울병원) ;
  • 심태선 (울산대학교 의과대학 서울아산병원) ;
  • 안중현 (가톨릭대학교 의과대학 인천성모병원) ;
  • 안철민 (연세대학교 의과대학 강남세브란스병원) ;
  • 우준희 (울산대학교 의과대학 서울아산병원) ;
  • 이남용 (성균관대학교 의과대학 삼성서울병원) ;
  • 이동건 (가톨릭대학교 의과대학 서울성모병원) ;
  • 이미숙 (경희대학교 의과대학 경희의료원) ;
  • 이상무 (건강보험심사평가원) ;
  • 이영선 (질병관리본부) ;
  • 이혁민 (관동대학교 의과대학 명지병원) ;
  • 정두련 (성균관대학교 의과대학 삼성서울병원)
  • Received : 2009.09.11
  • Accepted : 2009.09.22
  • Published : 2009.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

The successful treatment of community-acquired pneumonia requires appropriate, empirical antimicrobial therapy. The etiology and antimicrobial susceptibility of major pneumonia pathogens can differ by country. Therefore, the ideal treatment guidelines for community-acquired pneumonia should be based on the studies performed in each country. We developed a treatment guideline for community-acquired pneumonia for immunocompetent adults in Korea. This guideline was developed by the joint committee of the Korean Society for Chemotherapy, the Korean Society of Infectious Diseases, and the Korean Academy of Tuberculosis and Respiratory diseases.

Keywords

References

  1. Korea National Statistical Office. Annual report on the cause of death statistics 2007: Nationwide. Daejeon: Korea National Statistical Office; 2007
  2. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000;283:749-55 https://doi.org/10.1001/jama.283.6.749
  3. Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001;95:78-82 https://doi.org/10.1053/rmed.2000.0977
  4. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72 https://doi.org/10.1086/511159
  5. Jefferson H, Dalton HP, Escobar MR, Allison MJ. Transportation delay and the microbiological quality of clinical specimens. Am J Clin Pathol 1975;64:689-93 https://doi.org/10.1093/ajcp/64.5.689
  6. Yzerman EP, den Boer JW, Lettinga KD, Schellekens J, Dankert J, Peeters M. Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands. J Clin Microbiol 2002;40:3232-6 https://doi.org/10.1128/JCM.40.9.3232-3236.2002
  7. Roson B, Fernandez-Sabe N, Carratala J, Verdaguer R, Dorca J, Manresa F, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004;38:222-6 https://doi.org/10.1086/380639
  8. Kim S, Sung H, Kim DJ, Kim MN. Clinical relevance of positive NOW (TM) legionella urinary antigen test in a tertiary-care hospital in Korea. Korean J Lab Med 2006;26:93-7 https://doi.org/10.3343/kjlm.2006.26.2.93
  9. van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Bronsveld W, Jansen HM, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005;60:672-8 https://doi.org/10.1136/thx.2004.030411
  10. Lee JS, Chung JW, Koh Y, Lim CM, Jung YJ, Oh YM, et al. The etiologies and initial antimicrobial therapy outcomes in one tertiary hospital ICU-admitted patient with severe community-acquired pneumonia. Tuberc Respir Dis 2005;59:522-9 https://doi.org/10.4046/trd.2005.59.5.522
  11. Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003;123:1142-50 https://doi.org/10.1378/chest.123.4.1142
  12. Hahn TH, Jang MK, Kim SG, Lee JY, Lee JM, Kim DK, et al. The usefulness of quantitative culture of bronchoalveolar lavage fluid in the diagnosis of bacterial pneumonia. Korean J Med 1998;54:820-6
  13. Smith MD, Derrington P, Evans R, Creek M, Morris R, Dance DA, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003;41:2810-3 https://doi.org/10.1128/JCM.41.7.2810-2813.2003
  14. Murdoch DR, Laing RT, Cook JM. The NOW S. pneumoniae urinary antigen test positivity rate 6 weeks after pneumonia onset and among patients with COPD. Clin Infect Dis 2003;37:153-4 https://doi.org/10.1086/375610
  15. Labarere J, Stone RA, Obrosky DS, Yealy DM, Meehan TP, Fine JM, et al. Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: a propensity-adjusted analysis. Chest 2007;131:480-8 https://doi.org/10.1378/chest.06-1393
  16. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004;164:963-8 https://doi.org/10.1001/archinte.164.9.963
  17. Minogue MF, Coley CM, Fine MJ, Marrie TJ, Kapoor WN, Singer DE. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. Ann Emerg Med 1998;31:376-80 https://doi.org/10.1016/S0196-0644(98)70350-6
  18. Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996;51:1010-6 https://doi.org/10.1136/thx.51.10.1010
  19. Labarere J, Stone RA, Scott Obrosky D, Yealy DM, Meehan TP, Auble TE, et al. Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial. J Gen Intern Med 2006;21:745-52 https://doi.org/10.1111/j.1525-1497.2006.00510.x
  20. Bae JH, Lee MJ, Oh DR, Lee WJ, Kim SK. Modified triage method by pneumonia severity index for patients with community: acquired pneumonia. J Korean Soc Emerg Med 2002;13:129-34
  21. Choi SO, Park MS, Kang MH, Lee MK. Evaluation of risk factors for hospitalization and comparison of empiricregimens for efficacy and toxicity to treat community-acquired pneumonia. J Korean Soc Health Syst Pharm 2005;22:36-45
  22. Bont J, Hak E, Hoes AW, Schipper M, Schellevis FG, Verheij TJ. A prediction rule for elderly primary-care patients with lower respiratory tract infections. Eur Respir J 2007;29:969-75 https://doi.org/10.1183/09031936.00129706
  23. Fine MJ, Hough LJ, Medsger AR, Li YH, Ricci EM, Singer DE, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 1997;157:36-44 https://doi.org/10.1001/archinte.157.1.36
  24. Yealy DM, Auble TE, Stone RA, Lave JR, Meehan TP, Graff LG, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005;143:881-94 https://doi.org/10.7326/0003-4819-143-12-200512200-00006
  25. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82 https://doi.org/10.1136/thorax.58.5.377
  26. Teramoto S, Yamamoto H, Yamaguchi Y, Hanaoka Y, Ishii M, Hibi S, et al. Lower respiratory tract infection outcomes are predicted better by an age >80 years than by CURB-65. Eur Respir J 2008;31:477-8 https://doi.org/10.1183/09031936.00120807
  27. Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky DS, Meehan TP, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005;118:384-92 https://doi.org/10.1016/j.amjmed.2005.01.006
  28. Foley SC, Kelly EM, O'Neill SJ. Audit of the management of patients admitted with community acquired pneumonia. Ir Med J 2006;99:138-40
  29. Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002;166:717-23 https://doi.org/10.1164/rccm.2102084
  30. Ananda-Rajah MR, Charles PG, Melvani S, Burrell LL, Johnson PD, Grayson ML. Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. Scand J Infect Dis 2008;40:293-300 https://doi.org/10.1080/00365540701663381
  31. Marrie TJ, Huang JQ. Admission is not always necessary for patients with community-acquired pneumonia in risk classes IV and V diagnosed in the emergency room. Can Respir J 2007;14:212-6 https://doi.org/10.1155/2007/451417
  32. Valencia M, Badia JR, Cavalcanti M, Ferrer M, Agusti C, Angrill J, et al. Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest 2007;132:515-22 https://doi.org/10.1378/chest.07-0306
  33. Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998;158:1102-8 https://doi.org/10.1164/ajrccm.158.4.9803114
  34. Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 1995;22:219-23 https://doi.org/10.1016/0732-8893(95)00088-R
  35. Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159:2449-54 https://doi.org/10.1001/archinte.159.20.2449
  36. Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001;161:848-50 https://doi.org/10.1001/archinte.161.6.848
  37. Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, Armengou-Arxe A, Bisbe-Company V, Penarroja-Matutano G, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001;111:367-74 https://doi.org/10.1016/S0002-9343(01)00868-3
  38. Rhew DC, Riedinger MS, Sandhu M, Bowers C, Greengold N, Weingarten SR. A prospective, multicenter study of a pneumonia practice guideline. Chest 1998;114:115-9 https://doi.org/10.1378/chest.114.1.115
  39. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002;162:1278-84 https://doi.org/10.1001/archinte.162.11.1278
  40. Capelastegui A, Espana PP, Bilbao A, Martinez-Vazquez M, Gorordo I, Oribe M, et al. Pneumonia: criteria for patient instability on hospital discharge. Chest 2008;134:595-600 https://doi.org/10.1378/chest.07-3039
  41. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998;279:1452-7 https://doi.org/10.1001/jama.279.18.1452
  42. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneu-monia. Clin Infect Dis 2008;46:550-6 https://doi.org/10.1086/526526
  43. El Moussaoui R, Opmeer BC, de Borgie CA, Nieuwkerk P, Bossuyt PM, Speelman P, et al. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate- severe community-acquired pneumonia. Chest 2006;130:1165-72 https://doi.org/10.1378/chest.130.4.1165
  44. Chang J. Community acquired pneumonia. Korean J Med 2000;58:129-44
  45. Hyun I. Treatment of Outpatient community-acquired pneumonia. Korean J Med 2003;64:139-43
  46. Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008;32:726-32 https://doi.org/10.1183/09031936.00003608
  47. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965-71 https://doi.org/10.1378/chest.110.4.965
  48. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004;98:708-20 https://doi.org/10.1016/j.rmed.2004.04.007
  49. Rovira E, Martínez-Moragon E, Belda A, Gonzalvo F, Ripolles F, Pascual JM. Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime. Respiration 1999;66:413-8 https://doi.org/10.1159/000029424
  50. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998;92:1032-9 https://doi.org/10.1016/S0954-6111(98)90351-1
  51. O'Doherty B, Dutchman DA, Pettit R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxicillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997;40 Suppl A:73-81 https://doi.org/10.1093/jac/40.suppl_1.73
  52. Bruns AH, Oosterheert JJ, Prokop M, Lammers JW, Hak E, Hoepelman AI. Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. Clin Infect Dis 2007;45:983-91 https://doi.org/10.1086/521893
  53. Woo JH, Kang JM, Kim YS, Shin WS, Ryu JH, Choi JH, et al. A prospective multicenter study of community-acquired pneumonia in adults with emphasis on bacterial etiology. Korean J Infect Dis 2001;33:1-7
  54. Chung MH, Shin WS, Kim YR, Kang MW, Kim MJ, Jung HJ, et al. Etiology of community-acquired pneumonia surveyed by 7 university hospitals. Korean J Infect Dis 1997;29:339-59
  55. Yu CW, Park CW, Hwang BY, Song JY, Park O, Sohn JW, et al. Clinical features and prognosis of community-acquired pneumonia in the elderly patients. Korean J Infect Dis 2000;32:212-8 https://doi.org/10.1080/003655400750045367
  56. Sohn JW, Park SC, Choi YH, Woo HJ, Cho YK, Lee JS, et al. Atypical pathogens as etiologic agents in hospitalized patients with community-acquired pneumonia in Korea: a prospective multi-center study. J Korean Med Sci 2006;21:602-7 https://doi.org/10.3346/jkms.2006.21.4.602
  57. Song JH, Oh WS, Kang CI, Chung DR, Peck KR, Ko KS, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008;31:107-14 https://doi.org/10.1016/j.ijantimicag.2007.09.014
  58. Lee DD, Song EJ, Lee SM, Lee EY, Kim YS, Lee MK, et al. Frequency of legionella infection in patients with community-acquired pneumonia. Korean J Lab Med 2005;25:416-20
  59. Joo CH, Yoon HJ, Nam JH, Moon MS, Cho YK, Woo JH, et al. A prospective multicenter study on the etiological analysis of community-acquired pneumonia in adult patients in Korea: detection of mycoplasma pneumoniae and chlamydia pneumoniae infections. Korean J Infect Dis 2001;33:15-24
  60. Kim MJ, Cheong HJ, Sohn JW, Shim HS, Park DW, Park SC, et al. A prospective multicenter study of the etiological analysis in adults with community-acquired pneumonia: Legionella, Leptospira, Hantaan virus and orientia tsutsugamushi. Korean J Infect Dis 2001;33:24-31
  61. Song HS, Suh JH, Ahn JH, Yoon BI, Lee SJ, Lee MG, et al. The etiological role of legionella pneumophila in patients with community-acquired pneumonia in Korea. Tuberc Respir Dis 2001;50:409-14 https://doi.org/10.4046/trd.2001.50.4.409
  62. Lee SJ, Lee MG, Jeon MJ, Jung KS, Lee HK, Kishimoto T. Atypical pathogens in adult patients admitted with community-acquired pneumonia in Korea. Jpn J Infect Dis 2002;55:157-9
  63. Kim JH, Kwak YH, Na BK, Lee JY, Shin GC, Jung HS, et al. Viral etiology of community-acquired pneumonia in Korean adults. Korean J Infect Dis 2001;33:8-14
  64. Lew WJ, Lee EG, Bai JY, Kim HJ, Bai GH, Ahn DI, et al. An Internet-based surveillance system for tuberculosis in Korea. Int J Tuberc Lung Dis 2006;10:1241-7
  65. Lee SH, Hur GY, Jung KH, Lee SY, Lee SY, Kim JH, et al. Clinical investigation of tuberculous pneumonia. Tuberc Respir Dis 2004;57:19-24 https://doi.org/10.4046/trd.2004.57.1.19
  66. Park SD, Chung MH, Lee HM, Kim MK, Kang JS. A Case of scrub typhus in summer presenting as atypical pneumonia. Infect Chemother 2008;40:241-5 https://doi.org/10.3947/ic.2008.40.4.241
  67. Kim BN, Bae LG, Kim MN, Park SJ, Woo JH, Ryu J, et al. Risk factors for penicillin resistance and mortality in Korean adults with Streptococcus pneumoniae bacteremia. Eur J Clin Microbiol Infect Dis 2002;21:35-42 https://doi.org/10.1007/s10096-001-0650-8
  68. Lee NY, Song JH, Kim S, Peck KR, Ahn KM, Lee SI, et al. Carriage of antibiotic-resistant pneumococci among Asian children: a multinational surveillance by the Asian Network for Surveillance of Resistant Pathogens (ANSORP). Clin Infect Dis 2001;32:1463-9 https://doi.org/10.1086/320165
  69. Farrell DJ, Morrissey I, Bakker S, Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002;50 Suppl S1:39-47
  70. Schito GC, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003). Int J Antimicrob Agents 2005;26:479-85 https://doi.org/10.1016/j.ijantimicag.2005.04.022
  71. Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004;48:2101-7 https://doi.org/10.1128/AAC.48.6.2101-2107.2004
  72. Lee K, Lim CH, Cho JH, Lee WG, Uh Y, Kim HJ, et al. High prevalence of ceftazidime- resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004. Yonsei Med J 2006;47:634-45 https://doi.org/10.3349/ymj.2006.47.5.634
  73. Shin JH, Jung HJ, Kim HR, Jeong J, Jeong SH, Kim S, et al. Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea. Antimicrob Agents Chemother 2007;51:2625-7 https://doi.org/10.1128/AAC.00107-07
  74. Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, et al. Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. Antimicrob Agents Chemother 2007;51:453-60 https://doi.org/10.1128/AAC.00960-06
  75. Chang MW, Kim KH, Park ID, Kang KH, Kong EH, Jung MH, et al. Rapid detection of Mycoplasma pneumoniae and antimicrobial susceptibilities of the M. pneumoniae isolates. J Bacteriol Virol 2003;33:183-91
  76. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 2008;52:348-50 https://doi.org/10.1128/AAC.00779-07
  77. Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, et al. A worldwide perspective of atypical pathogens in community- acquired pneumonia. Am J Respir Crit Care Med 2007;175:1086-93 https://doi.org/10.1164/rccm.200603-350OC
  78. Robenshtok E, Shefet D, Gafter-Gvili A, Paul M, Vidal L, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2008:CD004418 https://doi.org/10.1002/14651858.CD004418.pub3
  79. Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005;115:1048-57 https://doi.org/10.1542/peds.2004-1276
  80. Granizo JJ, Gimenez MJ, Barberan J, Coronel P, Gimeno M, Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin Ther 2006;28:2061-9 https://doi.org/10.1016/j.clinthera.2006.12.010
  81. Lee MY, Ko KS, Oh WS, Park S, Lee JY, Baek JY, et al. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries. Int J Antimicrob Agents 2006;28:14-8
  82. Yi J, Lee JK, Kim EC. In vitro antimicrobial activity of cefditoren pivoxil, an oral cephalosporin, against major clinical isolates. Infect Chemother 2003;35:211-4
  83. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-408 https://doi.org/10.1001/archinte.160.10.1399
  84. Lautenbach E, Larosa LA, Kasbekar N, Peng HP, Maniglia RJ, Fishman NO. Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med 2003;163:601-5 https://doi.org/10.1001/archinte.163.5.601
  85. Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1,000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents 2004;24:479-84 https://doi.org/10.1016/j.ijantimicag.2004.06.010
  86. File TM Jr, Milkovich G, Tennenberg AM, Xiang JX, Khashab MM, Zadeikis N. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin 2004;20:1473-81 https://doi.org/10.1185/030079904X2556
  87. File TM Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community- acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007;60:112-20 https://doi.org/10.1093/jac/dkm119
  88. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-72 https://doi.org/10.1001/archinte.159.21.2562
  89. Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000;34:446-52 https://doi.org/10.1345/aph.19174
  90. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003;123:1503-11 https://doi.org/10.1378/chest.123.5.1503
  91. Mufson MA, Chan G, Stanek RJ. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started. Am J Med Sci 2007;333:161-7 https://doi.org/10.1097/MAJ.0b013e3180312cd5
  92. Cardoso MR, Nascimento-Carvalho CM, Ferrero F, Berezin EN, Ruvinsky R, Camargos PA, et al. Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia. Arch Dis Child 2008;93:221-5 https://doi.org/10.1136/adc.2006.111625
  93. Song JH, Jung SI, Ki HK, Shin MH, Ko KS, Son JS, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004;38:1570-8 https://doi.org/10.1086/420821
  94. Hong JH, Lee HS, Jung SH, Kim GW, Eom KS, Lee JM, et al. Prevalence and clinical outcome of penicillin-resistant pneumococcal pneumonia. Tuberc Respir Dis 2003;54:295-303 https://doi.org/10.4046/trd.2003.54.3.295
  95. Hwangbo B, Yoon HI, Lee SM, Choi SH, Yoo CG, Lee CT, et al. Clinical characteristics of pneumococcal bacteremia in adults: the effect of penicillin resistance on the mortality of patients with pneumococcal bacteremia. Tuberc Respir Dis 1999;47:184-94 https://doi.org/10.4046/trd.1999.47.2.184
  96. Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. Clin Infect Dis 2008;46:1499-509 https://doi.org/10.1086/587519
  97. Bhavnani SM, Ambrose PG. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008;60:59-64 https://doi.org/10.1016/j.diagmicrobio.2007.07.006
  98. Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med 2006;100:2129-36 https://doi.org/10.1016/j.rmed.2006.03.019
  99. Khashab MM, Xiang J, Kahn JB. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr Med Res Opin 2006;22:1997-2006 https://doi.org/10.1185/030079906X132505
  100. File TM. Community-acquired pneumonia. Lancet 2003;362:1991-2001 https://doi.org/10.1016/S0140-6736(03)15021-0
  101. Torres A, Serra-Batlles J, Ferrer A, Jimenez P, Celis R, Cobo E, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:312-8 https://doi.org/10.1164/ajrccm/144.2.312
  102. Leroy O, Saux P, Bedos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005;128:172-83 https://doi.org/10.1378/chest.128.1.172
  103. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170:440-4 https://doi.org/10.1164/rccm.200311-1578OC
  104. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-42 https://doi.org/10.1001/archinte.161.15.1837
  105. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002;162:1849-58 https://doi.org/10.1001/archinte.162.16.1849
  106. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-80 https://doi.org/10.1183/09031936.05.00055705
  107. Committee for The Japanese Respiratory Society guidelines for the management of respiratory infections. Guidelines for the management of community acquired pneumonia in adults, revised edition. Respirology 2006;11 Suppl 3:S79-133 https://doi.org/10.1111/j.1440-1843.2006.00937_1.x
  108. Craig WA. Pharmacodynamics of antimicrobials: general concepts and applications. In: Nightingale CH, Ambrose PG, Drusano GL, Murakawa T, editors. Antimicrobial phamacodynamics in theory and clinical practice. 2nd ed. New York: Informa healthcare; 2007. p. 1-19
  109. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-60 https://doi.org/10.1086/377539
  110. Rizzato G, Montemurro L, Fraioli P, Montanari G, Fanti D, Pozzoli R, et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J 1995;8:398-402 https://doi.org/10.1183/09031936.95.08030398
  111. Schonwald S, Skerk V, Petricevic I, Car V, Majerus-Misic L, Gunjaca M. Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur J Clin Microbiol Infect Dis 1991;10:877-80 https://doi.org/10.1007/BF01975847
  112. Menendez R, Torres A, Zalacain R, Aspa J, Martin Villasclaras JJ, Borderias L, et al. Risk factors of treatment failure in communityacquired pneumonia: implications for disease outcome. Thorax 2004;59:960-5 https://doi.org/10.1136/thx.2003.017756
  113. Arancibia F, Ewig S, Martinez JA, Ruiz M, Bauer T, Marcos MA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000;162:154-60 https://doi.org/10.1164/ajrccm.162.1.9907023
  114. Menendez R, Torres A, Rodriguez de Castro F, Zalacain R, Aspa J, Martín Villasclaras JJ, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004;39:1783-90 https://doi.org/10.1086/426028
  115. Celis R, Torres A, Gatell JM, Almela M, Rodriguez-Roisin R, Agusti-Vidal A. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 1988;93:318-24 https://doi.org/10.1378/chest.93.2.318
  116. Sanyal S, Smith PR, Saha AC, Gupta S, Berkowitz L, Homel P. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med 1999;160:346-8 https://doi.org/10.1164/ajrccm.160.1.9806048
  117. Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164:502-8 https://doi.org/10.1001/archinte.164.5.502

Cited by

  1. 호흡기내과 의사를 위한 폐렴 리뷰 vol.68, pp.6, 2009, https://doi.org/10.4046/trd.2010.68.6.319
  2. 지역사회 획득 폐렴환자의 중증도 평가에서 혈청 코티졸의 유용성 vol.69, pp.6, 2009, https://doi.org/10.4046/trd.2010.69.6.450
  3. Community Acquired Pneumonia vol.31, pp.7, 2010, https://doi.org/10.4082/kjfm.2010.31.7.503
  4. 지역사회획득 폐렴 vol.70, pp.1, 2011, https://doi.org/10.4046/trd.2011.70.1.1
  5. 중증 또는 비전형적 지역사회획득 폐렴으로 입원한 환자에서 호흡기 바이러스의 검출 빈도 vol.71, pp.5, 2009, https://doi.org/10.4046/trd.2011.71.5.335
  6. 지역사회획득 폐렴 환자의 중증도 보정 재원일수 분석 vol.12, pp.3, 2009, https://doi.org/10.5762/kais.2011.12.3.1234
  7. High-Dose Levofloxacin in Community-Acquired Pneumonia : A Randomized, Open-Label Study vol.32, pp.9, 2012, https://doi.org/10.1007/bf03261911
  8. Incidence and Cinical Characteristics of Severe Community-Acquired Pneumococcal Pneumonia: Comparisons with Non-Pneumoccocal Pathogens vol.82, pp.1, 2012, https://doi.org/10.3904/kjm.2012.82.1.52
  9. Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-infected Koreans vol.44, pp.3, 2009, https://doi.org/10.3947/ic.2012.44.3.93
  10. Severe Adenovirus Pneumonia vol.44, pp.5, 2009, https://doi.org/10.3947/ic.2012.44.5.407
  11. Methicillin-Resistant Staphylococcus Aureus 감염으로 인한 병원 내 감염 폐렴치료제로서 Linezolid와 Vancomycin의 비용-효과 분석 vol.3, pp.2, 2015, https://doi.org/10.34161/johta.2015.3.2.004
  12. Clinical practice guidelines for the management of community‐acquired pneumonia: A critical appraisal using the AGREE II instrument vol.74, pp.5, 2009, https://doi.org/10.1111/ijcp.13478
  13. Characteristics of fever and response to antipyretic therapy in military personnel with adenovirus-positive community-acquired pneumonia vol.7, pp.1, 2009, https://doi.org/10.1186/s40779-020-00235-x